United States securities and exchange commission logo
June 17, 2022
Chamath Palihapitiya
Chief Executive Officer
Social Capital Suvretta Holdings Corp. I
2850 W. Horizon Ridge Parkway, Suite 200
Henderson, NV 89052
Re: Social Capital
Suvretta Holdings Corp. I
Amendment No. 3 to
Registration Statement on Form S-4
Filed June 10, 2022
File No. 333-262706
Dear Mr. Palihapitiya:
We have reviewed your amended registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.
Please respond to this letter by amending your registration
statement and providing the
requested information. If you do not believe our comments apply to your
facts and
circumstances or do not believe an amendment is appropriate, please tell
us why in your
response.
After reviewing any amendment to your registration statement and
the information you
provide in response to these comments, we may have additional comments.
Unless we note
otherwise, our references to prior comments are to comments in our May
25, 2022 letter.
Amendment No. 3 to Registration Statement on Form S-4
Summary of the Proxy Statement/Prospectus
Our Development Pipeline, page 5
1. We acknowledge your
revised disclosure in response to our prior comment 1, which we
reissue in part. Please
also revise your Summary to clarify that while each of your product
candidates are
development programs oriented toward a single indication and specific
patient population, the
majority of your product candidates incorporate the same SSME-
based therapeutic
engine technology. We note your pipeline table continues to contain
text that is illegible.
Please revise accordingly.
Chamath Palihapitiya
FirstName LastNameChamath Palihapitiya
Social Capital Suvretta Holdings Corp. I
Comapany
June NameSocial Capital Suvretta Holdings Corp. I
17, 2022
June 17,
Page 2 2022 Page 2
FirstName LastName
Akili's Management's Discussion and Analysis of Financial Condition and Results
of Operations
Liquidity and Capital Resources
Cash Flows, page 306
2. Please expand your discussion and analysis of cash flows to include
the annual periods
presented in addition to the interim periods. Refer to Item 17(b)(5)
of Form S-4 and Item
303(b) of Regulation S-K for guidance.
You may contact Tracey Houser at 202-551-3736 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jane Park at 202-551-7439 or Christine Westbrook at 202-551-5019 with
any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Raaj Narayan, Esq.